|
Scientific Program
Tuesday, May 21, Afternoon
Wednesday, May 22, Morning
| Opening Session |
Opening Session |
OS |
4.30‐6.30 pm Welcome desk opening // Registration of participants
0 06:30 |
Welcome Remarks A. Dautry, J. Whitescarver, L. Matthiessen, J.F. Delfraissy
|
|
|
0 07:00 |
Special Opening Lecture: "The science of HIV/AIDS: much accomplished, much to do" A. Fauci
|
|
|
0 07:30 |
Welcome cocktail
|
|
|
| Plenary session |
Interactions at molecular levels: Viral strategies of replication and host restriction mechanisms |
PL |
| Chairs(s) : | Dr Simon WAIN-HOBSON | | | Prof. Robin WEISS |
7.45 am Welcome desk opening
1 08:40 |
Innate mechanisms of HIV-1 restriction and their viral countermeasures M. Malim Dept of Infectious Disease, King's College London, London, United Kingdom |
|
|
2 09:05 |
HIV assembly andmaturation: preparing the virus for infecting a new cell H.G. Kräusslich Universität Heidelberg, Germany |
|
|
3 09:30 |
From HIV inhibition to HIV escape: CCR5 conformations are differentially exploited by chemokines and R5 HIV-1 P. Colin1, Y. Bénureau1, I. Staropoli1, Y. Wang1, O. Hartley2, A. Brelot1, F. Arenzana-Seisdedos1, B. Lagane1 1Institut Pasteur, Paris, France 2University of Geneva, Geneva, Switzerland |
|
|
4 09:45 |
RNR2 repression by p21 restricts reverse transcription of HIV-1 and related-lentiviruses in macrophages A. Allouch4, A. David4, S. Amie6, H. Lahouassa3, F. Margottin-Goguet3-1-5, F. Barré-Sinoussi4-2, A. Saez-Cirion4, B. Kim6, G. Pancino4 1CNRS, UMR8104 2INSERM 3Inserm, U1016, Institut Cochin 4Unité de régulation des infections retrovirales, Institut pasteur de Paris 5Univ Paris Descartes, Paris, France 6Microbiology and Immunology, University of Rochester Medical Center, Rochester, United States |
|
|
| Plenary session |
Interactions at molecular levels: Viral strategies of replication and host restriction mechanisms |
PL |
| Chairs(s) : | Dr Eric HUNTER | | | Felix REY |
5 10:00 |
Molecular mechanisms of HIV‐1 post‐integration latency C. Van Lint Laboratory of Molecular Virology, University of Brussels (ULB), Belgium |
|
|
6 10:25 |
Using systems approaches to study HIV biology N.J. Krogan University of California, San Francisco, United States |
|
|
7 10:50 |
Cyclin T1 and CDK9 T-Loop Phosphorylation are downregulated during establishment of HIV-1 latency in Primary Resting Memory CD4+ T Cells M. Famiglietti1, S. Budhiraja2, A. Bosque3, A. Rice2, V. Planelles3 1San Raffaele Scientific Institute, Milano, Italy 2Baylor College of Medicine, Houston 3University of Utah, Salt Lake City, United States |
|
|
0 11:05 |
|
|
|
Afternoon
| Plenary session |
Interactions at tissue & systemic levels: Viral strategies of infection and host responses |
PL |
| Chairs(s) : | Thomas HOPE | | | M. Gianfranco PANCINO |
8 11:30 |
Virus‐host interactions during the first phases of infection and design principles for prevention of HIV‐1 transmission to women A. Haase University of Minnesota, Minneapolis, United States |
|
|
9 11:55 |
Innate immune responses in acute HIV‐1 infection: protective or pathogenic? P. Borrow2, A. Stacey2, A. Fenton-May2, O. Dibben2, E. Haygreen2, T. Emmerich2, N. Kim6, E. Marshall2, K. Lavender2, M. Cohen4, P. Goepfert3, I. Williams1, D. Wallace6, G. Shaw7, B. Hahn7, C. Ochsenbauer3, J. Kappes3, P. Norris8, A. Mcmichael2, B. Haynes5 1University College London, London 2Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom 3University of Alabama at Birmingham, Birmingham, Al 4University of North Carolina, Chapel Hill, Nc 5Duke University 6RTI International, Durham, Nc 7University of Pennsylvania, Pittsburgh, Pa 8Blood Systems Research Institute, San Francisco, United States |
|
|
10 12:20 |
The replicative capacity of transmitted HIV-1 contributes significantly to CD4 decline independent of VL and host contributions J. Prince3, D. Claiborne3, T. Yu2, S. Lakhi6, W. Kilembe6, L. Yue3, J. Gilmour1, J. Tang5, R. Kaslow5, S. Allen4, E. Hunter3-6 1International AIDS Vaccine initiative, London, United Kingdom 2Biostatistics 3Emory Vaccine Center 4Pathology and Laboratory Medicine, Emory University, Atlanta 5Medicine and Epidemiology, University of Alabama at Birmingham, Birmingham, United States 6Zambia Emory HIV Research Project, Lusaka, Zambia |
|
|
11 12:35 |
HIV exploits seminal cytokine network to promote its transmission to cervic0-vaginal tissue. Ex vivo study L. Margolis NICHD, Section of Intercellular Interactions, NIH, Bethesda, United States |
|
|
0 12:50 |
Lunch Buffet
|
|
|
0 13:45 |
Poster Session I
|
|
|
| Plenary session |
Interactions at tissue & systemic levels: Viral strategies of infection and host responses |
PL |
| Chairs(s) : | Dr Rafick SÉKALY | | | Dr Olivier SCHWARTZ |
12 02:45 |
A role for immune cell migration in the dissemination of HIV infection? T. Mempel2-1, T. Murooka2-1 1Harvard Medical School 2Massachusetts General Hospital, Boston, United States |
|
|
13 03:10 |
The human microbiome in health and immunodeficient states F.D. Bushman, G. Wu, J. Lewis, H. Li, K. Bittinger, E. Charlson, C. Hoffmann, R. Collman The Perleman School of Medicine at the University of Pennsylvania, Philadelphia, United States |
|
|
14 03:35 |
Deconvoluting the molecular arm race between HIV and the CD8+ T-cell response M.C. Iglesias2, M. Hashimoto3, K. Ladell4, P. Wilmann1, M. Takiguchi3, J. Rossjohn1, D. Price4, V. Appay2 1Monash University, Victoria, Australia 2U945 Infection and Immunity, INSERM, Paris, France 3Center for AIDS Research, Kumamoto, Japan 4Cardiff University School of Medicine, Cardiff, United Kingdom |
|
|
15 03:50 |
Widespread expression of HIV-1 p24-Gag protein in tissues of patients receiving combination antiretroviral therapy R. Fox2, B. Johnson3, K. Wong2, B. Larsen2, D. Westfall2, C. Fervet3, J. Elliott1, P. Anton1, J. Mullins2 1AIDS Institute, Department of Medicine , University of California Los Angeles, Los Angeles 2Department of Microbiology, University fo Washington 3Department of Comparative Medicine, University of Washington, Seattle, United States |
|
|
0 04:05 |
|
|
|
| Debate |
Debate: Which strategy to achieve a cure for HIV-1 infection? |
D |
| Chairs(s) : | Olivier LAMBOTTE |
0 02:45 |
J. Currier, S. Lewin, B. Autran, D. Margolis, P. Cannon
|
|
|
0 03:30 |
Community speaker debater A. Volny-Anne Paris, France |
|
|
0 03:45 |
|
|
|
Thursday, May 23, Morning
| Plenary session |
Inflammation, immune activation & pathogenesis |
PL |
| Chairs(s) : | Clifford LANE | | | Dr Marie-Lise GOUGEON |
16 04:30 |
The good, the bad and the ugly of immune activation D. Douek Vaccine Research Center, NIH/NIAID, Bethesda, United States |
|
|
17 04:55 |
The enigma of immune activation control in natural hosts M. Müller-Trutwin Unité des Régulations des Infections rétrovirales, Institut Pasteur, Paris, France |
|
|
18 05:20 |
Linking inflammation & immune activation with non‐AIDS disease: is the link causal? J. Lundgren Rigshospitalet/ Copenhagen Univ Hospital University of Copenhagen, Copenhagen, Denmark |
|
|
19 05:45 |
CD4+ T cells lacking SAMHD1 expression are highly proliferative in vivo and decrease during HIV-1 infection N. Ruffin2-3, V. Brezar2-3, D. Ayinde4, O. Schwartz4, J.D. Lelievre1-2, Y. Levy1-2-3, N. Seddiki2-3 1Clinical immunopathology, Hôpital Henri Mondor, Faculté de Médecine 2U955 Equipe 16, INSERM 3Vaccine Reaserch Institute, Créteil 4Unité Virus et Immunité, Département de Virologie, Institut Pasteur, Paris, France |
|
|
20 06:00 |
Experimental CD4 depletion prior to SIV infection in macaques results in encephalitis, massive macrophages and microglia infection, and rapid turnover of infected cells L. Micci2, R. Iriele2, X. Alvarez3, R. Geleziunas4, D. Hazuda7, A. Ortiz2, S. Pahwa6, M. Davenport1, J. Estes5, A. Lackner3, G. Silvestri2, M. Paiardini2 1The University of New South Wales, Sydney, Australia 2Emory University, Atlanta 3Tulane National Primate Research Center, Covington 4Gilead Sci, Inc., Foster City 5AIDS Cancer Virus Program, NCI-Frederick, Frederick 6University of Miami, Miami 7Merck Res Labs, West Point, United States |
|
|
21 06:15 |
Activation and gut-homing of plasmacytoid dendritic cells persists in the absence of HIV/SIV replication and contributes to residual chronic immune activation H. Li2, T. Evans2, J. Gillis2, P. Goepfert1, R K. Reeves2 1University of Alabama at Birmingham, Birmingham 2Harvard Medical School, Southborough, United States |
|
|
0 06:30 |
Community speaker remarks G. Gonsalves Yale Law School, New Haven, USA |
|
|
0 08:00 |
Congress dinner with Guests of Honor and Special Guests
With Guests of Honor and Special Guests
Opening address given by Dr Robert Gallo, Guest of Honor
Closing address given by Prof. Luc Montagnier, Guest of Honor
|
|
|
| Plenary session |
Clinical & translational Research |
PL |
| Chairs(s) : | Dr Carl DIEFFENBACH | | | Prof. Salim ABDOOL KARIM |
22 09:00 |
Gene Therapy approach for HIV‐1 infection M. Cavazzana-Calvo2-7-5, P. Frange3, C. Parolin1, G. Pancino6, F. Spavanello1, S. Blanche3, E. Oksenhendler4 1Dept of Histology, Microbiology & Biotechnology, University of Padua, Padua 2Biotherapy Dept 3Pediatric Immuno-Haematology Unit, APHP Hôpital Necker-Enfants Malades 4Clinical Immunology Unit, APHP, Hôpital Saint-Louis 5GHU Ouest Biotherapy Clinical Investigation Center, INSERM, APHP 6Regulation Unit for Retroviral Infections, Institut Pasteur 7IMAGINE Institute, Université Paris Descartes, Paris, France |
|
|
23 09:25 |
HIV‐1 Neutralizing Antibodies: Understanding Nature's Pathways. J. Mascola NIH/NIAID/VRC, Bethesda, United States |
|
|
24 09:50 |
Antiretroviral agents prevent HIV transmission: Where do we go from here? M. Cohen University of North Carolina, Chapel Hill, United States |
|
|
25 10:15 |
Impact of an enhanced prenatal HIV counselling on male partner HIV testing, couple counselling and HIV-free survival of infants in Yaoundé, Cameroon. ANRS 12127-Prenahtest trial P. Tchendjou Tankam1-6, J. Orne-Gliemann4, P. Koki Ndombo2, T. Mossus1, F. Eboko5, E. Balestre4, A. Ngo Essounga1, D. Amassana1, A.C. Bissek3, M. Tejiokem1-6, F. Dabis4, &. For The Prenahtest Anrs 12127 Study Group. 1Epidemiologie et Sante Publique, Centre Pasteur Cameroun 2Centre Mère Enfant, Fondation Chantal Biya 3Division de la Recherche opérationnelle en santé, Ministère de la Santé Publique, Yaoundé, Cameroon 4INSERM U897, Institut de Santé Publique, Epidémiologie et Développement. Université Bordeaux Segalen, Bordeaux 5UMR 912 IRD-INSERM-U2, Institut de Recherche pour le développement, Marseille 6Réseau International des Instituts Pasteur, Institut Pasteur Paris, Paris, France |
|
|
26 10:30 |
Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production M. Perreau1, A.L. Savoye1, E. De Grignis1, J.M. Corpataux2, R. Cubas5, E.K. Haddad5, L. De Leval3, C. Graziosi1, G. Pantaleo1-4 1Division of Immunology and Allergy 2Division of Thoracic Surgery 3Institute of Pathology, Lausanne University Hospital 4Swiss Vaccine Research Institute, Lausanne, Switzerland 5Vaccine and Gene Therapy Institute, Port St Lucie, United States |
|
|
27 10:45 |
Four Days a Week and Less on Proper Antiviral Combinations Provided Long-Term Maintenance on 84 Patients’ HIV / The ICCARRE PROJECT (1) J. Leibowitch1, D. Mathez1, P. De Truchis1, D. Le Dû1, J.C. Melchior1, B. Autran2, C. Perrronne1, J. Izopet3, J. David4 1Infectious Disease Dept, Raymond Poincaré Hospital, Garches 2Immunity and Infection Laboratory, Pitié-Salpétrière Hospital, Paris 3Microbiology, Purpan Hospital, Toulouse, France 4Harvard School of Public Health, Boston, United States |
|
|
0 11:00 |
Community speaker remarks J. Gapiya Niyonzima ANSS, Centre Turiho, Kigobe, Burundi |
|
|
0 11:15 |
|
|
|
Afternoon
| Plenary session |
Strategies for HIV control & cure |
PL |
| Chairs(s) : | Christine ROUZIOUX | | | Giuseppe PANTALEO |
28 11:40 |
Why curing HIV might be easier than assumed S. Deeks UCSF, San Francisco, United States |
|
|
29 12:05 |
Natural and treatment induced control of HIV/SIV infections A. Saez-Cirion Unité des Régulations des Infections rétrovirales, Institut Pasteur, Paris, France |
|
|
30 12:30 |
Association between negative regulators and HIV persistence during ART: Identifying potential therapeutic targets for eradication strategy R. Fromentin, S. Dafonseca, M.B. Lawani, W. Bakeman, C. Vandergeeten, R.P. Sekaly, N. Chomont Vaccine and Gene Therapy Institute-Florida, Port St Lucie, United States |
|
|
0 12:45 |
Lunch Buffet
|
|
|
0 13:45 |
Poster Session II
|
|
|
|